The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases

Keyphrases

• Endocannabinoid System 100%
• Endocannabinoids 100%
• Kidney Disease 100%
• CB1 Receptor 100%
• Obesity 66%
• CB1 Receptor Antagonist 66%
• Mouse Model 33%
• Central Nervous System 33%
• Oxidative Stress 33%
• Rat Model 33%
• Marijuana 33%
• Cannabinoid Receptor 2 33%
• Cannabinoid Receptor 1 (CB1R) 33%
• Peripherally Restricted 33%
• Cannabinoids 33%
• Peripheral Organs 33%
• Therapeutic Potential 33%
• Deleterious Effects 33%
• Diabetes 33%
• Chronic Disease 33%
• Type 1 Diabetes Mellitus (T1DM) 33%
• Type 2 Diabetes Mellitus (T2DM) 33%
• Kidney 33%
• Pharmacological Approaches 33%
• CB2 Receptor 33%
• Neuropsychiatric Adverse Events 33%
• Anandamide 33%
• Ion Transport 33%
• Renal Fibrosis 33%
• Renal Disease 33%
• 2-Arachidonoylglycerol (2-AG) 33%
• Inflammatory Fibrosis 33%
• Endogenous Lipids 33%
• Renal Vascular 33%
• Normal Renal Function 33%
• Receptor Blockers 33%
• Nephron 33%
• Renal Pathology 33%
• Renal Cell 33%
• Vascular Hemodynamics 33%
• Lipophilic Ligands 33%
• Nervous-peripheral 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Cannabinoid 1 Receptor 100%
• Endocannabinoid 100%
• Endocannabinoid System 100%
• Kidney Disease 100%
• Cannabinoid 2 Receptor 66%
• Cannabinoid 1 Receptor Antagonist 66%
• Disease 33%
• Mouse Model 33%
• Inflammation 33%
• Adverse Event 33%
• Rat Model 33%
• Cannabis 33%
• Insulin Dependent Diabetes Mellitus 33%
• Chronic Disease 33%
• Cannabinoid Receptor 33%
• Anandamide 33%
• Receptor Blocking Agent 33%
• Kidney Fibrosis 33%
• Cannabinoid 33%
• Non Insulin Dependent Diabetes Mellitus 33%